Based on HUTCHMED's own website:
https://www.hutch-med.com/esmo2020-phase1-1b-trial-of-fruquintinib-in-patients-with-advanced-solid-tumors/
Right at the bottom (under "Disclosure") Imugene has even provided an advisory/consultancy role in 2020 for their colorectal trial.
So they definitely know of us.
Ann: Annual Report to shareholders, page-47
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.002(3.57%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.9¢ | 5.6¢ | $448.0K | 7.718M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 549100 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 1097920 | 17 |
View Market Depth
| Last trade - 12.52pm 23/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |